This study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, cholangiocarcinoma (bile duct cancer), or mesothelioma that expresses mesothelin (a protein found on some cancer cells). SynKIR-110 uses your own immune cells, called T cells, which are specially modified in a lab to target these cancer cells. The main goal of this study is to see how safe SynKIR-110 is and if it's possible to give this treatment. Researchers will also look for early signs of whether the treatment is working. You might be able to join if you are 18 or older, have one of these cancers that has come back or spread after at least one other treatment, and have a good general health status (ECOG performance status of 0 to 1). This study plans to enroll up to 42 participants.

Study design

This is a Phase 1, first-in-human, multicenter, open-label, dose-escalation pilot study. Up to 42 participants will be treated in different groups to find the safest dose.

What's involved

You will go through a screening period, receive chemotherapy followed by a single infusion of SynKIR-110, and then have follow-up visits for 12 months or until your disease progresses.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months or until their disease progresses, whichever comes first. After this, they may be invited to a long-term safety follow-up study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.